Pages that link to "Q31130672"
Jump to navigation
Jump to search
The following pages link to Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. (Q31130672):
Displaying 50 items.
- Considerations for observational research using large data sets in radiation oncology (Q24289442) (← links)
- Real world evidence: An Indian perspective (Q28074506) (← links)
- International comparison of comparative effectiveness research in five jurisdictions: insights for the US (Q28292892) (← links)
- Assessing the outcomes of implantable cardioverter defibrillator treatment in a real world setting: results from hospital record data (Q30599499) (← links)
- Standards should be applied in the prevention and handling of missing data for patient-centered outcomes research: a systematic review and expert consensus (Q30699551) (← links)
- Can administrative data be used to measure chemotherapy side effects? (Q30877306) (← links)
- Real world data: Additional source for making clinical decisions (Q30975806) (← links)
- Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes (Q31046934) (← links)
- USING CLAIMS DATA FOR EVIDENCE GENERATION IN MANAGED ENTRY AGREEMENTS. (Q31058117) (← links)
- Real-world data in the United Kingdom: opportunities and challenges (Q31110524) (← links)
- Big Data: transforming drug development and health policy decision making (Q31126744) (← links)
- Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials (Q31155420) (← links)
- Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis (Q33305959) (← links)
- Integrating patients into meaningful real-world research (Q33440620) (← links)
- Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry (Q33576871) (← links)
- Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development (Q33772852) (← links)
- Observational studies: a valuable source for data on the true value of RA therapies (Q33779130) (← links)
- Effectiveness of anti-tumor necrosis factor agents in the treatment of rheumatoid arthritis: observational study (Q33932391) (← links)
- Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. (Q34009569) (← links)
- A systematic review of economic evaluations of interventions to tackle cardiovascular disease in low- and middle-income countries (Q34116368) (← links)
- Health-care data collecting, sharing, and using in Thailand, China mainland, South Korea, Taiwan, Japan, and Malaysia (Q34134806) (← links)
- Temporal variability of antibiotics fluxes in wastewater and contribution from hospitals. (Q34548303) (← links)
- The clinical decision analysis using decision tree (Q34608270) (← links)
- Pharmacoeconomic studies in Nepal: the need of the hour (Q34650925) (← links)
- Do economic evaluations of targeted therapy provide support for decision makers? (Q34974213) (← links)
- Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta-analysis (Q35068631) (← links)
- Protocol for the economic evaluation of the diarrhea alleviation through zinc and oral rehydration salt therapy at scale through private and public providers in rural Gujarat and Uttar Pradesh, India (Q35104420) (← links)
- Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study (Q35675851) (← links)
- Healthcare Databases in Thailand and Japan: Potential Sources for Health Technology Assessment Research. (Q35839046) (← links)
- Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy (Q35884411) (← links)
- Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study (Q35905994) (← links)
- Is real world evidence influencing practice? A systematic review of CPRD research in NICE guidances (Q36085309) (← links)
- Real World Data in Adaptive Biomedical Innovation: A Framework for Generating Evidence Fit for Decision-Making (Q36132510) (← links)
- Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study (Q36171531) (← links)
- Systematic Review and Meta-Analysis of Tacrolimus versus Ciclosporin as Primary Immunosuppression After Liver Transplant (Q36182011) (← links)
- Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey (Q36528355) (← links)
- How many cardiovascular events can be prevented with optimal management of high-risk Canadians? (Q37098243) (← links)
- Cost-effectiveness analysis of fesoterodine flexible dose in newly diagnosed patients with overactive bladder in routine clinical practice in Spain (Q37300812) (← links)
- Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma (Q37327618) (← links)
- Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD. (Q37468663) (← links)
- Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer (Q37729193) (← links)
- Real-world resource use and costs of adjuvant treatment for stage III colon cancer (Q38174218) (← links)
- Current situation and challenge of registry in China (Q38245893) (← links)
- Evidence informed decision making: the use of "colloquial evidence" at nice (Q38492354) (← links)
- Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy. (Q38627241) (← links)
- PHEDRA: using real-world data to analyze treatment patterns and ibrutinib effectiveness in hematological malignancies (Q38647162) (← links)
- How can real-world evidence be used in practice to demonstrate drug value and improve patient care? (Q38686411) (← links)
- Methods for estimating costs in patients with hyperlipidemia experiencing their first cardiovascular event in the United Kingdom (Q38716031) (← links)
- Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program. (Q38748387) (← links)
- Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund (Q38814615) (← links)